Common Photosensitizing Drugs Increase Skin Cancer Risk
By Lori Solomon HealthDay Reporter
TUESDAY, April 1, 2025 -- Some commonly prescribed photosensitizing drugs increase skin cancer risk, according to a study published online March 18 in Photodermatology, Photoimmunology & Photomedicine.
Gustav Boelsgaard Christensen, from Skåne University Hospital in Lund, Sweden, and colleagues assessed whether the use of commonly prescribed photosensitizing drugs increases skin cancer risk.
The researchers found that hormone replacement therapy significantly increased the risk for basal cell carcinoma (BCC; hazard ratio [HR], 1.24), cutaneous squamous cell carcinoma (cSCC; HR 1.23), and cutaneous malignant melanoma (cM; HR, 1.31), with estrogen driving the risk. There was a trend observed between a higher risk for BCC and cM and higher doses of estrogen treatment. Among individuals using diuretics, loop diuretics were associated with increased cSCC risk (HR, 1.6), including a positive association between risk and dose. Thiazide use was tied to increased risks for BCC (HR, 1.25) and cM (HR, 1.41). There was a possible curvilinear association between nonsteroidal anti-inflammatory drugs and BCC and cSCC.
"We suggest that physicians should advise female patients prescribed estrogen, thiazides, or loop diuretics to limit their sun exposure," the authors write. "Future well-designed prospective studies are warranted to further investigate the relationships between common photosensitizing drugs and the risk of skin cancer."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Type of Hormone Therapy Used After Menopause Affects Memory Performance
FRIDAY, Aug. 29, 2025 -- Earlier age at menopause is associated with lower scores on all cognitive domains, and menopausal hormone therapy (MHT) differentially affects cognition...
High Response to PD-1 Therapy Seen in Unresectable Desmoplastic Melanoma
TUESDAY, Aug. 19, 2025 -- Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) therapy, according to a study...
Rate of Sexual Dysfunction Similar in Middle-Aged, Older Women
MONDAY, Aug. 18, 2025 -- Older women experience female sexual dysfunction (FSD) at similar rates as midlife women but report less sexual distress, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.